Publications by authors named "Amit M Oza"

100Publications

Across barriers: poly ADP-ribose polymerase inhibitors beyond progression in high grade serous ovarian cancer with brain metastases.

Int J Gynecol Cancer 2020 Sep 30. Epub 2020 Sep 30.

Medical Oncology and Hematology, Princess Margaret Hospital Cancer Centre, Toronto, Ontario, Canada

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/ijgc-2020-001849DOI Listing
September 2020

Biomarkers of outcome to weekly paclitaxel in epithelial ovarian cancer.

Gynecol Oncol 2020 Nov 8;159(2):539-545. Epub 2020 Sep 8.

Division of Medical Oncology & Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada; University of Toronto, Toronto, ON, Canada. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2020.08.032DOI Listing
November 2020

Moving Beyond BRCA-Incorporating Molecular Assays into Ovarian Cancer Trials.

Clin Cancer Res 2020 Oct 14;26(20):5271-5273. Epub 2020 Aug 14.

Princess Margaret Cancer Centre, University Health Network. Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-20-2429DOI Listing
October 2020

Adjuvant treatment in early stage cervical cancer-does more equal better?

Int J Gynecol Cancer 2020 Sep 20;30(9):1467-1468. Epub 2020 Jul 20.

Medical Oncology & Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/ijgc-2020-001840DOI Listing
September 2020

Efficacy and safety updates of poly ADP-ribose polymerase (PARP) inhibitor maintenance in ovarian cancer from ASCO 2020.

Int J Gynecol Cancer 2020 Aug 9;30(8):1256-1257. Epub 2020 Jul 9.

Medical Oncology & Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/ijgc-2020-001723DOI Listing
August 2020

COVID-19 Testing in Patients with Cancer: Does One Size Fit All?

Clin Cancer Res 2020 09 2;26(18):4737-4742. Epub 2020 Jul 2.

Division of Medical Oncology & Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-20-2224DOI Listing
September 2020

Measurement Tool of Chemotherapy Sensitivity in Advanced Ovarian Cancer.

Clin Cancer Res 2020 Sep 29;26(17):4432-4434. Epub 2020 Jun 29.

Department of Medical Oncology and Hematology, Princess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-20-1376DOI Listing
September 2020

Overcoming Platinum and PARP-Inhibitor Resistance in Ovarian Cancer.

Cancers (Basel) 2020 Jun 17;12(6). Epub 2020 Jun 17.

Division of Medical Oncology & Hematology, Bras Family Drug Development Program, Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2M9, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers12061607DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7352566PMC
June 2020

The role of maintenance therapy in ovarian cancer.

Authors:
Amit M Oza

Clin Adv Hematol Oncol 2020 Feb;18(2):98-101

University of Toronto, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
February 2020

Manage wisely: poly (ADP-ribose) polymerase inhibitor (PARPi) treatment and adverse events.

Int J Gynecol Cancer 2020 Jul 9;30(7):903-915. Epub 2020 Apr 9.

Medical Oncology & Hematology, Princess Margaret Hospital Cancer Centre, Toronto, Ontario, Canada

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/ijgc-2020-001288DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7398227PMC
July 2020

Heterogeneous alteration of the ERBB3-MYC axis associated with MEK inhibitor resistance in a -mutated low-grade serous ovarian cancer patient.

Cold Spring Harb Mol Case Stud 2019 12 13;5(6). Epub 2019 Dec 13.

Bras Family Drug Development Program, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario M5G 1Z5, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1101/mcs.a004341DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6913142PMC
December 2019

Metformin in Gynecologic Cancers: Opening a New Window for Prevention and Treatment?

Clin Cancer Res 2020 02 26;26(3):523-525. Epub 2019 Nov 26.

Division of Medical Oncology & Hematology, Bras Family Drug Development Program, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-19-3645DOI Listing
February 2020

Outcome according to residual disease (surgeon's report vs pre-chemotherapy imaging) in patients with bevacizumab-treated ovarian cancer: Analysis of the ROSiA study.

J Surg Oncol 2019 Sep 31;120(4):786-793. Epub 2019 Jul 31.

Department of Medical Oncology, Princess Margaret Hospital, University of Toronto, Toronto, ON, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jso.25647DOI Listing
September 2019

Molecular characterization of gastric-type endocervical adenocarcinoma using next-generation sequencing.

Mod Pathol 2019 12 15;32(12):1823-1833. Epub 2019 Jul 15.

Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41379-019-0305-xDOI Listing
December 2019

Targeting TGFβ Pathway in Adult Granulosa Cell Tumor: Opening Pandora's Box?

Clin Cancer Res 2019 Sep 11;25(18):5432-5434. Epub 2019 Jul 11.

Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-19-1605DOI Listing
September 2019

Epithelial ovarian cancer: Evolution of management in the era of precision medicine.

CA Cancer J Clin 2019 07 17;69(4):280-304. Epub 2019 May 17.

Chief, Division of Medical Oncology and Hematology; Director, Cancer Clinical Research Unit; and Director, Bras Drug Development Program, Princess Margaret Cancer Centre, University Health Network and Mt. Sinai Health System, Toronto, ON, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3322/caac.21559DOI Listing
July 2019

Wanna Get Away? Maintenance Treatments and Chemotherapy Holidays in Gynecologic Cancers.

Am Soc Clin Oncol Educ Book 2019 Jan 17;39:e152-e166. Epub 2019 May 17.

1 Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/EDBK_238755DOI Listing
January 2019

Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial.

Lancet Oncol 2019 05 1;20(5):636-648. Epub 2019 Apr 1.

Division of Gynecologic Oncology, Arizona Oncology (US Oncology Network), University of Arizona College of Medicine, Creighton University School of Medicine at St Joseph's Hospital, Phoenix, AZ, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(19)30029-4DOI Listing
May 2019

Epithelial ovarian cancer.

Lancet 2019 Mar;393(10177):1240-1253

Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0140-6736(18)32552-2DOI Listing
March 2019

Tailoring Ovarian Cancer Treatment: Implications of Mutations.

Cancers (Basel) 2019 Mar 23;11(3). Epub 2019 Mar 23.

Division of Medical Oncology & Hematology, Princess Margaret Cancer Center, Toronto, ON M5G 2M9, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers11030416DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6468364PMC
March 2019

Advances in prediction for ovarian cancer treatment stratification.

Authors:
Amit M Oza

Nat Rev Clin Oncol 2019 02;16(2):75-76

Princess Margaret Cancer Centre, University Health Network and Mount Sinai Hospital University of Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41571-018-0147-3DOI Listing
February 2019

Targeting Angiogenesis: Taming the Medusa of Ovarian Cancer.

Hematol Oncol Clin North Am 2018 12;32(6):1041-1055

Department of Medicine, University of Toronto, ON, Canada; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, 700 University Avenue, Suite 7-925, Toronto, ON M5G 1Z5, Canada.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S08898588183075
Publisher Site
http://dx.doi.org/10.1016/j.hoc.2018.07.008DOI Listing
December 2018

Moving From Mutation to Actionability.

Am Soc Clin Oncol Educ Book 2018 May;38:495-503

From the Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX; University of Toronto, Department of Medicine, Toronto, ON, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/EDBK_199665DOI Listing
May 2018

The role of niraparib for the treatment of ovarian cancer.

Future Oncol 2018 Oct 1;14(25):2565-2577. Epub 2018 Jun 1.

Division of Medical Oncology & Hematology, Princess Margaret Cancer Centre & Department of Medicine, University of Toronto, Toronto, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2018-0101DOI Listing
October 2018

Resisting RECIST-Uniformity Versus Clinical Validity.

Int J Gynecol Cancer 2017 10;27(8):1619-1627

*Auckland City Hospital, Auckland, New Zealand; †Prince of Wales Hospital, Sydney, Australia; ‡Princess Margaret Cancer Centre, Toronto, Ontario Canada; §Department of Radiation Oncology, Loyol University, Chicago, IL; ‖Instituto Valenciano de Oncologia, Valencia, Spain; ¶Université Paris Descartes, AP-HP, Hôpitaux Universitaires Paris Centre, Paris, France; and #Gynecologic Group Intergroup, Kingston, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/IGC.0000000000001062DOI Listing
October 2017

Niraparib for the treatment of ovarian cancer.

Expert Opin Pharmacother 2017 Apr 7;18(6):631-640. Epub 2017 Apr 7.

a Division of Medical Oncology and Hematology, Department of Medicine, Princess Margaret Cancer Centre , University of Toronto , Toronto , Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14656566.2017.1297423DOI Listing
April 2017

Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition.

J Clin Oncol 2017 Apr 21;35(11):1240-1249. Epub 2017 Feb 21.

Stephanie Lheureux, Jeff P. Bruce, Julia V. Burnier, Katherine Karakasis, S.Y. Cindy Yang, Rene Quevedo, Tiantian Li, Mark Dowar, Valerie Bowering, Trevor J. Pugh, and Amit M. Oza, Princess Margaret Cancer Centre; Stephanie Lheureux, Patricia A. Shaw, Blaise A. Clarke, S.Y. Cindy Yang, Rene Quevedo, Trevor J. Pugh, and Amit M. Oza, University of Toronto; Patricia A. Shaw and Blaise A. Clarke, University Health Network, Toronto, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.71.3677DOI Listing
April 2017

Treatment strategies for endometrial cancer: current practice and perspective.

Curr Opin Obstet Gynecol 2017 02;29(1):47-58

Drug Development Program, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/GCO.0000000000000338DOI Listing
February 2017

Efficacy and Safety of Bevacizumab-Containing Therapy in Newly Diagnosed Ovarian Cancer: ROSiA Single-Arm Phase 3B Study.

Int J Gynecol Cancer 2017 01;27(1):50-58

*Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada; †Hôpital Tenon, Assistance Publique-Hôpitaux de Paris, and Alliance Pour la Recherche en Cancérologie, Paris, France; ‡Chemotherapy Department of State Budgetary Healthcare Institution, Clinical Oncology Dispensary #1, Krasnodar Region Ministry of Healthcare, Krasnodar, Russia; §Gynecologic Oncology Department, Sheba Medical Center, Tel Hashomer, Israel; ∥University Hospital 12 de Octubre, Madrid, Spain; ¶Medical Department, Gustave Roussy, Villejuif, France; #Department of Clinical Oncology, Oncology Center Prof. F. Lukaszczyka, Bydgoszcz, Poland; **Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece; ††Ente Ospedaliero Ospedali Galliera, Genoa, Italy; ‡‡Riga East University Hospital, Latvian Oncology Centre, Riga, Latvia; §§Medical Oncology Department, MD Anderson Cancer Center Madrid, Madrid, Spain; ∥∥Pérola Byington Hospital/Faculty of Medicine University of São Paulo, São Paulo, Brazil; ¶¶Medical Oncology Department, Centre François Baclesse, Caen, France; ##Policlinico Sant'Orsola-Malpighi, Bologna, Italy; ***Division of Gynecology and Obstetrics, Department of Experimental and Clinical Medicine, University of Pisa, Pisa, Italy; †††Global Medical Affairs, F. Hoffmann-La Roche Ltd, Basel, Switzerland; and ‡‡‡Division of Medical Gynecologic Oncology, European Institute of Oncology and University of Milano-Bicocca, Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/IGC.0000000000000836DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5181120PMC
January 2017

Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.

N Engl J Med 2016 12 7;375(22):2154-2164. Epub 2016 Oct 7.

From the Nordic Society of Gynecological Oncology and Rigshospitalet-Copenhagen University Hospital, Copenhagen (M.R.M.), Odense University Hospital (J.H.) and European Network for Gynacological Oncological Trial and Research Unit of General Practice, Institute of Public Health, University of Southern Denmark, Odense (R.D.C.) - all in Denmark; University of Arizona and Creighton University-Phoenix, Phoenix (B.J.M.), and Arizona Oncology Associates, Tuscon (B.J.M., J.B.) - all in Arizona; Princess Margaret Consortium, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto (A.M.O.), British Columbia Cancer Agency, Vancouver (A.V.T.), and McGill University-McGill University Health Centre, Montreal (L.G.) - all in Canada; Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) and the University of Munich, Munich (S.M.), and Kliniken Essen Mitte, Essen (A.B.) - both in Germany; Grupo Español de Investigación en Cáncer de Ovario (GEICO) and Hospital Universitario La Paz (A.R.), and GEICO and M.D. Anderson Cancer Center Madrid (A.G.-M.), Madrid; French Investigator Group for Ovarian and Breast Cancer (GINECO) and Institut du Cancer de Montpellier, Montpellier (M.F.), and GINECO and Centre Antoine Lacassagne, Nice (P.F.) - both in France; National Cancer Research Institute and UCL Cancer Institute, University College London, London (J.A.L.); Multicenter Italian Trials in Ovarian Cancer/Mario Negri Gynecologic Oncology Group, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale dei Tumori, Milan (D.L.); Belgium and Luxembourg Gynecological Oncology Group and University of Leuven, Leuven, Belgium (I.V.); Kaplan Medical Center, Rehovot, Israel (N.E.B.-B.); AGO-Austria and Medical University Innsbruck, Innsbruck, Austria (C.M.); Central and Eastern European Gynecologic Oncology Group and Uniwersytet Medyczny w Poznaniu, Poznan, Poland (R.M.); Stanford Comprehensive Cancer Institute, Stanford (J.S.B.), and Cedars-Sinai Medical Center, West Hollywood (B.J.R.) - both in California; Oslo University Hospital, Radiumhospitalet, Oslo (A.D.); Northside Hospital, Atlanta (B.B.); Universitetssjukhuset, Linköping, Sweden (P.R.); and Veristat, Southborough (J.P.B.), Tesaro, Waltham (S.A.), and Dana-Farber Cancer Institute, Boston (U.A.M.) - all in Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1611310DOI Listing
December 2016

Phase I Study Evaluating WEE1 Inhibitor AZD1775 As Monotherapy and in Combination With Gemcitabine, Cisplatin, or Carboplatin in Patients With Advanced Solid Tumors.

J Clin Oncol 2016 12 31;34(36):4371-4380. Epub 2016 Oct 31.

Suzanne Leijen, Robin M.J.M. van Geel, and Jan H.M. Schellens, The Netherlands Cancer Institute, Amsterdam; Jan H.M. Schellens, Utrecht University, Utrecht, the Netherlands; Anna C. Pavlick, New York University Medical Center, New York, NY; Lee Rosen, University of California Los Angeles, Santa Monica, CA; Raymond Lam, Shelonitda Rose, Mark A. Lee, Tomoko Freshwater, and Stuart Shumway, Merck, Kenilworth, NJ; Geoffrey I. Shapiro, Dana-Farber Cancer Institute, Boston, MA; Albiruni R. Abdul Razak and Amit M. Oza, Princess Margaret Hospital, Toronto, Ontario, Canada; Raoul Tibes, University Hospital of Würzburg, Würzburg; Tim Demuth, Sandoz AG, Holzkirchen, Germany; and Li Wen Liang, Merck Sharp & Dohme R&D, Beijing, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.67.5991DOI Listing
December 2016

Paradigm Shift in the Management Strategy for Epithelial Ovarian Cancer.

Am Soc Clin Oncol Educ Book 2016 ;35:e247-57

From the Department of Gynecologic Oncology, Saitama Medical University International Medical Center, Saitama, Japan; Department of Gynecology and Obstetrics, University of British Columbia, Vancouver, Canada; Division of Medical Oncology and Hematology, Bras Family Drug Development Program, Princess Margaret Cancer Centre, Toronto, Canada; Department of Gynecology and Obstetrics, Kyoto University, Kyoto, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/EDBK_158675DOI Listing
January 2017

Ovarian Cancer and BRCA1/2 Testing: Opportunities to Improve Clinical Care and Disease Prevention.

Front Oncol 2016 11;6:119. Epub 2016 May 11.

Drug Development Program, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto , Toronto, ON , Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fonc.2016.00119DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4862980PMC
May 2016

Endometrial cancer-targeted therapies myth or reality? Review of current targeted treatments.

Eur J Cancer 2016 05 25;59:99-108. Epub 2016 Mar 25.

Drug Development Program, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, 610 University Avenue, Toronto, Ontario, Canada. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2016.02.016DOI Listing
May 2016

New Targeted Agents in Endometrial Cancer: Are We Really Making Progress?

Curr Oncol Rep 2016 Apr;18(4):23

Department of Medicine, Division of Medical Oncology, Princess Margaret Cancer Center, University of Toronto, Toronto, ON, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11912-016-0507-zDOI Listing
April 2016

Current and emerging treatment options in the management of advanced ovarian cancer.

Expert Opin Pharmacother 2016 Jun 16;17(8):1063-76. Epub 2016 Mar 16.

a Division of Medical Oncology and Hematology, Princess Margaret Hospital , University of Toronto , Toronto , Ontario , Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/14656566.2016.1159295DOI Listing
June 2016

Sorafenib Increases Tumor Hypoxia in Cervical Cancer Patients Treated With Radiation Therapy: Results of a Phase 1 Clinical Study.

Int J Radiat Oncol Biol Phys 2016 Jan 18;94(1):111-117. Epub 2015 Sep 18.

Department of Medical Oncology, Princess Margaret Cancer Center, University Health Network, Toronto, Canada; Department of Medicine, University of Toronto, Toronto, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijrobp.2015.09.009DOI Listing
January 2016

Discordance between the results and conclusions of ICON7 - Authors' reply.

Lancet Oncol 2015 Oct;16(13):e478-9

St James Institute of Oncology, St James University Hospital, Leeds, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(15)00311-3DOI Listing
October 2015

Ovarian cancer treatment: The end of empiricism?

Cancer 2015 Sep 10;121(18):3203-11. Epub 2015 Jun 10.

Division of Medical Oncology and Hematology, Bras Family Drug Development Program, Princess Margaret Cancer Center, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.29481DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4744728PMC
September 2015

Discrepancies in drug approvals: A global dilemma.

Cancer 2015 Sep 16;121(18):3360-1. Epub 2015 Jun 16.

Division of Medical Oncology and Haematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.29484DOI Listing
September 2015

Randomized Phase II Trial of Ridaforolimus in Advanced Endometrial Carcinoma.

J Clin Oncol 2015 Nov 15;33(31):3576-82. Epub 2015 Jun 15.

Amit M. Oza, Princess Margaret Cancer Centre, Toronto, ON, Canada; Sandro Pignata, Istituto Nazionale Tumori "Fondazione G Pascale"-Istituto Di Ricovero e Cura a Carattere Scientifico, Naples, Italy; Andres Poveda, Instituto Valenciano de Oncologia, Valencia, Spain; Mary McCormack, University College Hospital, London; Andrew Clamp, Institute of Cancer Sciences-University of Manchester and the Christie National Health Service Foundation Trust, Manchester, United Kingdom; Benjamin Schwartz, Island Gynecologic Oncology, Brightwaters, NY; Jonathan Cheng, Xiaoyun Li, and Kristy Campbell, Merck, Kenilworth, NJ; and Pierre Dodion and Frank G. Haluska, ARIAD Pharmaceuticals, Cambridge, MA.

View Article

Download full-text PDF

Source
http://jco.ascopubs.org/content/33/31/3576.full.pdf
Web Search
http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2014.58.8871
Publisher Site
http://dx.doi.org/10.1200/JCO.2014.58.8871DOI Listing
November 2015

Cancer precursor lesions in the BRCA population at the time of prophylactic salpingo-oophorectomy: Accuracy of assessment and potential surrogate marker for prevention.

Gynecol Oncol 2015 Aug 10;138(2):235-7. Epub 2015 Jun 10.

Department of Medical Oncology, Princess Margaret Cancer Centre, Toronto Canada. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2015.06.014DOI Listing
August 2015

Safety evaluation of olaparib for treating ovarian cancer.

Expert Opin Drug Saf 2015 Aug 8;14(8):1305-16. Epub 2015 Jun 8.

University of Toronto, Princess Margaret Cancer Centre, Division of Medical Oncology and Hematology, Drug Development Program , 610 University Avenue, Toronto, Ontario , Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/14740338.2015.1045875DOI Listing
August 2015

Stage I granulosa cell tumours: A management conundrum? Results of long-term follow up.

Gynecol Oncol 2015 Aug 21;138(2):285-91. Epub 2015 May 21.

Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Canada. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2015.05.011DOI Listing
August 2015

Targeting the microenvironment in ovarian cancer.

Lancet Oncol 2015 May 14;16(5):485-6. Epub 2015 Apr 14.

Division of Medical Oncology and Haematology, Bras Family Drug Development Program, Princess Margaret Cancer Centre, Toronto, ON, M5G 2M9, Canada. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(15)70157-9DOI Listing
May 2015

Outcomes and endpoints in cancer trials: bridging the divide.

Lancet Oncol 2015 Jan 29;16(1):e43-52. Epub 2014 Dec 29.

University of Toronto Princess Margaret Cancer Centre, Toronto, ON, Canada. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(14)70380-8DOI Listing
January 2015

Outcomes and endpoints in trials of cancer treatment: the past, present, and future.

Lancet Oncol 2015 Jan 29;16(1):e32-42. Epub 2014 Dec 29.

Princess Margaret Cancer Centre, Toronto, Canada. Electronic address:

View Article

Download full-text PDF

Source
http://www.thelancet.com/pdfs/journals/lanonc/PIIS1470-2045(
Web Search
http://dx.doi.org/10.1016/S1470-2045(14)70375-4DOI Listing
January 2015

Performance characteristics of a brief Family History Questionnaire to screen for Lynch syndrome in women with newly diagnosed endometrial cancer.

Gynecol Oncol 2015 Feb 19;136(2):311-6. Epub 2014 Dec 19.

Division of Gynecologic Oncology, Princess Margaret Hospital/University Health Network, 610 University Ave., Toronto, Ontario M5G 2M9, Canada; Department of Obstetrics and Gynecology, University of Toronto, 27 King's College Circle, Toronto, Ontario M5S 2J7, Canada. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2014.12.023DOI Listing
February 2015

Non-target progression--the fine line between objectivity and subjectivity.

Eur J Cancer 2014 Dec 18;50(18):3271-2. Epub 2014 Oct 18.

Division of Medical Oncology and Haematology, Bras Family Drug Development Program, Princess Margaret Cancer Centre, Toronto, Ontario, Canada. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2014.08.021DOI Listing
December 2014

Intermediate clinical endpoints: a bridge between progression-free survival and overall survival in ovarian cancer trials.

Cancer 2015 Jun 21;121(11):1737-46. Epub 2014 Oct 21.

UCL Cancer Institute, University College London, London, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.29082DOI Listing
June 2015